share_log

Olema Pharmaceuticals Announced That It Will Present New Clinical Data From The Company's Ongoing Phase 1b/2 Clinical Study Of Palazestrant In Combination With Cdk4/6 Inhibitor Ribociclib In Berlin, Germany

Olema Pharmaceuticals Announced That It Will Present New Clinical Data From The Company's Ongoing Phase 1b/2 Clinical Study Of Palazestrant In Combination With Cdk4/6 Inhibitor Ribociclib In Berlin, Germany

Olema Pharmicals宣布将提供该公司正在德国柏林进行的帕拉西司朗与Cdk4/6抑制剂Ribociclib联合使用的1b/2期临床研究的新临床数据
Benzinga ·  05/08 07:23

Olema Pharmaceuticals Announced That It Will Present New Clinical Data From The Company's Ongoing Phase 1b/2 Clinical Study Of Palazestrant In Combination With Cdk4/6 Inhibitor Ribociclib In Berlin, Germany

Olema Pharmicals宣布将提供该公司正在德国柏林进行的帕拉西司朗与Cdk4/6抑制剂Ribociclib联合使用的1b/2期临床研究的新临床数据

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发